RAS is an oncogene, which is a gene that when mutated causes cancer. RAS is a family of genes including KRAS, HRAS, and NRAS and is commonly mutated in cancer. RAS mutations, usually in the KRAS protein, occur in about one in three cases of non-small cell lung cancer.
These gene mutations are found only in cancer cells and cause RAS proteins, which act a bit like traffic lights, to be stuck on green much longer than they are in normal cells. The result is a nearly never-ending flow of growth signals into the cell. Those signals cause the cell to become cancerous.
Dana-Farber’s Alice Shaw, MD, PhD, chief of Strategic Partnerships and co-director of the Center for RAS Therapeutics, started studying RAS oncogenes at the beginning of her career as a medical oncologist and physician-scientist. Her research focused on how RAS mutations drive cancer, and how to selectively target RAS mutant cancers. Over a decade later, as head of translational clinical oncology at Novartis, Shaw oversaw the clinical development of a new KRAS inhibitor.
Shaw’s focus now is on bringing RAS experts together in one center to advance treatments for patients with RAS-mutated cancer, including lung cancer.
“The landscape of RAS therapeutics is highly complex and dynamic,” says Shaw. “It’s such an exciting time, but it can also feel overwhelming. The Center for RAS Therapeutics is going to be incredibly valuable in helping us evaluate emerging new therapies in order to select the most promising ones for patients with RAS-mutated lung cancer.”
Are there approved treatments for RAS-mutated lung cancer?
Currently there are two RAS inhibitors approved by the U.S. Food and Drug Administration (FDA) for the treatment of RAS-mutated non-small cell lung cancer. Those inhibitors target a specific RAS mutation called KRAS G12C, which is the most common KRAS mutation in non-small cell lung cancer. These inhibitors are approved for patients who have already been treated with at least one therapy and have advanced or metastatic disease that is positive for the KRAS G12C mutation.

Prior to the approval of these therapies, patients with RAS driven non-small cell lung cancers had no targeted therapy options and could only be treated with chemotherapy or immunotherapy. However, not everyone taking these RAS inhibitors respond to the drugs, and relapses do occur.
To enhance the efficacy of these drugs, they are now being tested in combination with immunotherapy, chemotherapy, or both as first-line treatment for advanced non-small cell lung cancer. One example is a clinical trial led by Dana-Farber’s Pasi Jänne, MD, PhD.
“We know these medicines can work, but we want them to work better, so we’re combining them with other effective medicines right off the bat as the first treatment the patient receives,” says Jia Luo, MD, a Dana-Farber thoracic oncologist.

Are there up-and-coming RAS inhibitors being worked on for advanced non-small cell lung cancer?
There are multiple types of RAS inhibitors in phase 3 clinical trials, which are the pivotal late-phase trials regulators at the FDA use to determine whether a drug should be approved. There are also numerous earlier phase clinical trials testing newer and better RAS inhibitors. Most trials are for patients with advanced or metastatic cancer.
Examples include:
- Next-generation RAS inhibitors that target KRAS G12C are being tested in clinical trials at Dana-Farber. One such medicine, divarasib, has shown promise in late-stage clinical trials, with results suggesting that it may be more effective than currently approved KRAS G12C inhibitors. The data is being reviewed by regulators to determine if it should become an approved medicine.
- KRAS mutation specific inhibitors like KRAS G12D inhibitors specifically target the G12D mutation that is found in 4 to 5% of non-small cell lung cancer cases. Dana-Farber offers multiple clinical trials of KRAS G12D inhibitors.
- Multi-selective RAS (or pan KRAS) inhibitors target all mutant forms of RAS or KRAS. One example is daraxonrasib, which has made headlines following successful clinical trial results in pancreatic cancer. Early results from testing the drug in non-small cell lung cancer are encouraging. Other multi-selective inhibitors are also being tested in clinical trials at Dana-Farber.
- TCR-Engineered T cells designed to recognize and attack KRAS mutations are also being tested at Dana-Farber in non-small cell lung cancer and other RAS-mutant cancers.
Dana-Farber’s Center for RAS therapeutics has a team of experts in RAS mutant cancers that meet regularly to maintain an up-to-date list of all clinical trials of RAS-targeted therapies.
Will I be treated with daraxonrasib if I have RAS-mutant non-small cell lung cancer?
Currently, daraxonrasib is only available to patients with non-small cell lung cancer via clinical trials. So far, early results from the initial phase 1 trial of daraxonrasib in non-small cell lung cancer have been promising. Follow-on trials are testing the drug by itself and in combination with other promising treatments in RAS mutant non-small cell lung cancer.
Daraxonrasib is not yet FDA approved for any form of cancer, though it is available through an expanded access program for patients with pancreatic cancer.
Are any RAS-targeted therapies being evaluated for early-stage non-small cell lung cancer?
Dana-Farber investigator Narjust Florez, MD, has begun testing a RAS-targeted therapy for patients with stage II and III non-small cell lung cancer that has a known KRAS G12C mutation. The trial is comparing divarasib, a KRAS G21C inhibitor, with immunotherapy or observation after surgery to remove the cancer.
How will I know if I have a RAS mutation?
A RAS mutation is detected in cancer cells through genetic sequencing of cells from a patient’s tumor biopsy. Recently, guidelines have been updated to support genetic sequencing of all stages of lung cancer, which means that Medicare and most health insurances will cover the test. In the past, stage IV metastatic tumors were routinely sequenced, but stage I, II, and III tumors were tested only as part of research.
“It’s really exciting to know that patients everywhere can learn if they have a RAS-mutant cancer that might make them a good fit for a clinical trial,” says Luo.
Learn more about the clinical trials and clinical research related to RAS-mutated lung cancer.